BCL2 and acute myeloid leukemia: In summary, our findings suggest that BCL-2 and MCL1 are key determinants of pro-survival activity in both treatment naive and chemoresistant AML and that simultaneous targeting of both proteins appears necessary for optimal pro-apoptotic activity [14].